Safety and tolerability of switching to asenapine from other antipsychotic agents: pooled results from two randomized multicenter trials in stable patients with persistent negative symptoms in schizophrenia
Pilar Cazorla,1 Mary Mackle,2 Jun Zhao,2 Xianwei Ha,2 Armin Szegedi21Formerly, Merck Rahway, 2Merck, Rahway, NJ, USABackground: In clinical practice, clinicians often need to switch antipsychotic medications in patients with schizophrenia to optimize treatment outcomes. Here, we describe the safety...
Enregistré dans:
Auteurs principaux: | Mackle M, Cazorla P, Zhao J, Ha X, Szegedi A |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2012
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/e482743f111c49358c612581ca9a0d0f |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Asenapine effects on individual Young Mania Rating Scale items in bipolar disorder patients with acute manic or mixed episodes: a pooled analysis
par: Cazorla P, et autres
Publié: (2013) -
Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder
par: Gao K, et autres
Publié: (2013) -
Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study
par: Durgam S, et autres
Publié: (2017) -
Role of sublingual asenapine in treatment of schizophrenia
par: Citrome L
Publié: (2011) -
Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case report
par: Okazaki K, et autres
Publié: (2017)